Business Wire

Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity

Share

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Personal, a next-generation, tumor-informed liquid biopsy assay designed to detect and quantify molecular residual disease (MRD) and recurrence in patients previously diagnosed with cancer. NeXT Personal delivers industry-leading MRD sensitivity down to the 1 part-per-million range, an approximately 10- to 100-fold improvement over other available technologies. This enables earlier detection across a broader variety of cancers and stages, including typically challenging early stage, low mutational burden, and low-shedding cancers.

NeXT Personal leverages whole genome sequencing of a patient’s tumor to identify up to 1,800 specially-selected somatic variants that are subsequently used to create a personalized liquid biopsy panel for each patient. The targeted panel is then used to sequence millions of unique DNA molecules from a patient’s blood sample. Aggregation of signal across these sequences using proprietary algorithms enables part-per-million sensitivity. Personalis’ innovative methods are covered by its broad range of early and subsequent intellectual property filings.

Going beyond other tumor-informed MRD assays, NeXT Personal also simultaneously detects and quantifies clinically relevant mutations in circulating tumor DNA (ctDNA) that may be used in the future to help guide therapy, when cancer is detected. These include known targetable cancer mutations, drug resistance mutations, and new variants which can emerge and change over time, especially under therapeutic pressure.

“With this launch, Personalis is extending what an MRD product can deliver,” said John West, Personalis’ Chief Executive Officer. “With its dramatic increase in sensitivity, we expect to address a range of tumors which were out of reach with earlier technologies. With its broader information content, we also go beyond detection of a tumor, to provide the additional characterization needed to understand and eventually help manage disease.”

“NeXT Personal addresses the need for higher sensitivity assays, opening the door for earlier detection and more sensitive monitoring of patient response to therapy across a broader range of cancers and stages. Today’s release is targeted towards biopharma partners and clinical collaborators. In 2022, we plan to release NeXT Personal as a clinical test, which we expect will yield opportunities for earlier intervention and treatment for cancer patients,” said Dr. Richard Chen, Personalis’ Chief Medical Officer and SVP of R&D.

About Personalis

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to Veterans Affairs' Million Veteran Program. To enable cancer and population sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit www.personalis.com and follow Personalis on LinkedIn and Twitter.

Forward-Looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of NeXT Personal or the Personalis NeXT Platform, Personalis’ business opportunities, leadership, plans or expectations, the coverage or breadth of the company’s intellectual property, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678

Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westmount Realty Capital Recapitalizes 6.1 Million Square-Foot Industrial Portfolio in Chicago and Milwaukee26.1.2022 21:33:00 EET | Press release

Westmount Realty Capital, a privately held, Dallas-based commercial real estate company announced today that it is partnering with a fund managed by the Real Estate Group of Ares Management Corporation, a leading global alternative investment manager, to recapitalize a 51-asset industrial portfolio totaling 6.1 million square feet located in established industrial submarkets of Chicago and Milwaukee. Westmount and Ares acquired the institutional-quality portfolio of logistics, bulk distribution, and last-mile industrial properties from a Partners Group Westmount joint venture. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005816/en/ Westmount Realty Capital and Ares Management Corporation recapitalized and acquired an institutional-quality portfolio of logistics, bulk distribution, and last-mile industrial properties totaling 6.1 million square feet located in established industrial submarkets of Chicago and Milwaukee

artnet AG: Artnet Joins New Deutsche Börse ESG Visibility Hub26.1.2022 20:25:00 EET | Press release

Artnet AG, the leading platform for art market data and media, and the global marketplace for fine art online-only sales, is pleased to announce that it has joined the new Deutsche Börse ESG Visibility Hub. Investors increasingly expect transparency from companies with regard to sustainability. A high level of disclosure and comprehensible reporting enables ESG-related data (ESG translates to Environment, Society, Governance) to be included in investment decisions - with the aim of lowering the risks and positive impact of an investment. Artnet AG has been a pioneer within the art market for over 30 years. By engaging with ESG reporting and initiatives, Artnet continues its ethos of spearheading positive change and sustainable business practices. Artnet strives to continuously offer an environment where its employees, customers, and stakeholders can do what they love in a sustainable way. Furthermore, Artnet values its role in assisting clients in engaging with fine art and collectible

VitreaLab, Quantopticon, Luminess Win Big at SPIE Startup Challenge26.1.2022 19:35:00 EET | Press release

Yesterday, at a ceremony during SPIE Photonics West, VitreaLab, with its laser-lit chip focused on the 2D and 3D display market – a technology which enables more power-efficient displays – was announced the winner of the $10,000 top prize at the 12th annual SPIE Startup Challenge. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005652/en/ Jonas Zeuner of VitreaLab, center, is joined onstage by Jenoptik's Song Yop Chung, left, and Ralf Kuschnereit, right. (Photo: Business Wire) With cash prizes all provided by Jenoptik, Quantopticon, a designer of simulation software for quantum photonic hardware manufacturers, received $5,000 for second place. Luminess came in third, winning $2,500, with their versatile platform for safer, more sensitive, and more reliable X-ray medical imaging. The SPIE Startup Challenge, which showcases new businesses, products, and technologies that address critical needs with photonics, is supported

ABO - Óskare Capital: Partnership Announcement26.1.2022 17:30:00 EET | Press release

Alpha Blue Ocean (ABO) and Óskare Capital are announcing today the formation of a strategic partnership to collaborate on investment opportunities associated with cannabis plant-based medicines as well as synthetic molecules that target the mammalian Endocannabinoid system (ECS). Both companies recognize that there are also investment opportunities related to products, infrastructure technologies and services which will be part of the associated ecosystem for this sector. With a strong focus in Europe, the teams will work together to identify those companies with the greatest potential to enter global markets. This sector is nascent in Europe and is still in early stages of development on the pharmaceutical side; both companies see this as a “blue ocean” opportunity as the market emerges in the years to come. The partnership is based on biotech, agtech, and life science expertise; track records in the European VC; and strong access to deal flow, all of which will enable the partnership

Staffmark Group Leverages Rimini Street Support for Oracle PeopleSoft Powering Payroll for 35,000 Employees a Week26.1.2022 17:00:00 EET | Press release

Rimini Street, Inc. (NASDAQ: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Staffmark Group, an award-winning staffing and recruitment firm, continues to leverage Rimini Street to support the company’s PeopleSoft system environment support and maintenance. Since making the switch to Rimini Street, Staffmark has significantly improved the quality, responsiveness and depth of PeopleSoft support available to its internal IT team, enabled faster tax, legal and regulatory updates, and plans to reinvest support cost savings in service offering innovation and enhancements such as AI analysis capabilities and automated job posting functionality for employers and jobseekers – a vital part of its competitive market strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005280/en/

Covetrus Taps César França as President, Global Proprietary Brands26.1.2022 17:00:00 EET | Press release

Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of César França as President, Global Proprietary Brands. França will lead the companywide development and management of Covetrus’ global proprietary brand portfolio, including the current Covetrus, Kruuse, Vi, Roadrunner Pharmacy, and Calibra brands. The company will rely on his vision and expertise to develop categories, build strategic partnerships, and identify external growth opportunities. França brings more than 25 years of leadership and experience in brand development and management, marketing, sales, business development, and general management to Covetrus. “We’re delighted to welcome César to this new and dynamic role,” said Matt Malenfant, Chief Commercial Officer at Covetrus. “César is a positive, trusted leader with a foundational belief in the power of people and brands. He will work closely with our commercial and operations teams to ensure effectiveness an

o9 Solutions Raises $295 Million From Strategic Investors to Continue its Growth Across Industry Verticals & Markets26.1.2022 16:00:00 EET | Press release

o9 Solutions, a leading enterprise AI software platform provider for transforming planning and decision-making speed and quality in companies across industry verticals, today announced that it has received equity investments totaling $295 million from General Atlantic, including BeyondNetZero, its climate investing venture, Generation Investment Management, a pure-play sustainability investment manager, and existing investor KKR. This significant investment will help o9 build on its momentum and accelerate growth for its AI-powered Integrated Business Planning platform it calls the “Digital Brain” across industry verticals and markets. It will also help o9 drive continued innovation in R&D, industry knowledge models and partner ecosystem development that will help companies implement o9’s game-changing platform faster and realize greater value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005218/en/ Chakri Gottemukka

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom